Logo

ABBV logo AbbVie Inc. (ABBV) price target and intrinsic value estimate

ABBV's fair price estimate is $136.8.

This valuation is based on a fair P/E of 13.1 and EPS estimates of $10.48, and calculated using the pevaluation method.

ABBV is currently trading at $200.51 (47% overvalued).

The median analyst price target for ABBV is $210.5.

Analyst price targets range from $170.0 to $240.0

Is ABBV overvalued or undervalued?

ABBV is overvalued by 47% using the pevaluation method.

ABBV is undervalued by 5% compared to median analyst price targets.

Current price $200.5
Fair price $136.8
Low analyst price target $170.0
Median analyst price target$210.5
High analyst price target $240.0

Define your own market model and access personalized fair price estimates today!

ABBV logo
AbbVie Inc.
ABBV
200.51 (0.00%) 0.00
Fair price estimates:
Low ($7.86 EPS)
$102.6
Average ($10.48 EPS)
$136.8
High ($13.10 EPS)
$171.0
My holdings
My holdings:
Shares:
Cost basis:
Health Care
Biotechnology
Market cap:$ 354.17(B)
Enterprise value:$ 411.99(B)
Div. yield:3.09%
P/E:69.86
P/FCF:N/A
P/B:52.22
DescriptionNotes
AbbVie Inc. discovers develops manufactures and sells pharmaceuticals worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis psoriatic disease and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis ankylosing spondylitis atopic dermatitis axial spondyloarthropathy ulcerative colitis and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer endometriosis and central precocious puberty and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech Inc.; and Genentech Inc. as well as collaboration with Tentarix Biotherapeutics LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.
PEvaluation
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide
None/narrowMediumWideVery wide
Fair P/E
Margin of safety
EPS estimates
Currentprice:200.5Buy price109.5Fair price136.8
Analyst recommendations
Price targets
Current price: 200.5
Low
$170.0
Median
$210.5
High
$240.0
S. Sell:
0
Sell:
0
Hold:
10
Buy:
7
S. Buy:
9
TTM Financials
Income
RevenueGrossNet
Balance sheet
Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Cash flow
CFOCFICFF
Growth estimates
Revenue Upgrade
EPS10.2%

Historical financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Shares (Basic)Shares (Diluted)
Per share data
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
ROICROAROCEROE
Market Cap.
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Market Cap.